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Abstract: The aim of this review is to provide an overview of genitourinary health in peri- and
postmenopause, particularly of vulvovaginal atrophy (VVA), which is part of genitourinary syndrome
(GSM). This condition has a high prevalence among post-menopausal women and negatively a↵ects
a woman’s quality of life. Epidemiology, signs, symptoms, diagnostic criteria of VVA and target
treatments for restoring vaginal health are discussed in light of the most recent literature. Issues
related to this condition in menopausal women are under-diagnosed, lack objective diagnostic criteria,
and consequently under-treated. Over the years, many treatments have been developed but their
long-term e↵ectiveness and safety have yet to be clearly defined. Patients are often dissatisfied and
stop treatment, suggesting the need for a more personalized and tailored approach to achieve better
compliance and thereby e↵ectiveness. The aim of this paper is to provide an overview of the most
recent literature on VVA in order to help the gynecologist in the management of this condition.
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1. Introduction
The condition of hypoestrogenism related to menopause has a strong negative impact on vaginal
and urinary health, often leading to a condition called genitourinary syndrome (GSM), a term
introduced by the International Society for the Study of Women’s Sexual Health and the North
American Menopause Society in 2014 [1]. GSM is associated with genital signs and symptoms such as
dryness, burning, irritation, and sexual symptoms such as discomfort or pain, and impaired sexual
function. This condition, previously known as vulvovaginal atrophy (VVA), may also be accompanied
by urinary signs and symptoms such as urinary incontinence, dysuria, stranguria, and frequent urinary
tract infections [2]. Unlike other menopausal symptoms, VVA is a chronic condition that tends to
worsen throughout the years after menopause. It therefore requires prompt and long-term therapy to
achieve good results and to avoid the recurrence of symptoms when treatment is stopped.
The aim of this paper is to provide an overview of the most recent literature on VVA that would
help to sensitize the clinician toward the diagnosis and treatment of this condition [3,4]. This condition
has important consequences in the daily life of post-menopausal women and in their relationships [5,6].
Considering that women spend a third of their life in menopause, it is essential to recognize and treat
this syndrome in order to restore the vaginal and vulvar epithelium and ultimately improve quality
of life.
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The rationale of treatment is the restoration of normal vaginal and vulvar physiology that leads to
the alleviation of symptoms. Many options have been developed over the years such as local, systemic
hormonal, and non-hormonal treatments or energy-based treatments that could potentially fulfill
most women’s needs and preferences, thus improving the quality of post-menopausal women’s lives
(Figures A1 and A2).
2. Epidemiology of Vulvovaginal Atrophy
VVA a↵ects most peri- and postmenopausal women with a prevalence ranging from 36% to
almost 90%, according to the most recent surveys. It has recently been reported that this condition
is also already present in pre-menopausal years with a prevalence of 19% in women aged 40–45
(Table A1) [7–13].
In spite of its high prevalence, VVA is still under-diagnosed and under-treated. Most women do
not discuss their symptoms with their gynecologist for various reasons; often because they believe it is
just a natural part of aging or because they are uncomfortable talking about it. Often they are unaware
that there is treatment for the syndrome, or because of time constrains and/or perceived lack of interest
of their healthcare provider. Whatever the reason, the lack of diagnosis still remains one of the major
issues in the care of this condition [10,14].
Women tend to self-medicate using over-the-counter drugs that are sometimes ine↵ective or not
e↵ective enough and are therefore stopped, leaving the woman to live with the condition untreated [14].
3. Clinical Signs and Symptoms of Vulvovaginal Atrophy
The drop in circulating hormone levels, especially estrogens, represents the main trigger
determining vulvovaginal atrophy. The vaginal epithelia of post-menopausal women display flattened
epithelial surfaces with features of keratinization and the absence of papillae. Multiple layers of
parabasal cells with higher nucleus to cytoplasm ratio and few intermediate and superficial cells are
present in which glycogen stores are reduced. This leads to a decrease in the number of Lactobacilli
resulting in an increase in vaginal pH [15]. The low percentage of Lactobacilli and the increase
in the relative proportion of anaerobic bacteria found in post-menopausal women may predispose
symptomatic VVA, although not all studies consistently report this association [16–18].
Hypo estrogenic vaginal states typically also include changes in the connective tissue composition
with decreased type I/III collagen ratio, which leads to reduced tissue strength [19]. Thinning of the
vaginal epithelium increases susceptibility to trauma, resulting in bleeding, petechiae, and ulceration
with any type of pressure including sexual activity or a simple gynecological maneuver. Thinning also
exposes the underlying connective tissue, which is more vulnerable to inflammation or infection.
Due to these histological changes, clinical signs at the vaginal level include anything from dryness
and insu cient hydration, redness, loss of elasticity, petechiae, ulceration, inflammation, atypical
secretions, to fibrosis and vaginal obliteration. The most frequent signs at a vulvar level include
reduction in tissue thickness, labia agglutination, loss of pubic hair, and scratching lesions due to
itching. Consequent symptoms include vaginal dryness and superficial dyspareunia with a prevalence
of 78% and 76%, respectively [20], which can be associated with itching, a burning sensation, and
susceptibility to mechanical insults, leucorrhoea, or atypical secretions. At a vulvar level, the most
frequent symptoms are burning, pain, increased susceptibility to physical and chemical irritants, and
mechanical insults [21].
All of these changes have a great impact on women’s sexuality and relationships [22]. The
REVIVE study suggested that VVA symptoms have a significant impact on the patients’ ability to
achieve pleasurable relations (74%) and spontaneity (70%). Seventy-five percent of sexually active
post-menopausal women with VVA were reported to have a significantly reduced sex drive as a direct
consequence of the symptoms related to this condition [20]. A 2014 study, showed that most women
were worried that vaginal discomfort could have long-term e↵ects on their relationship [23].
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4. Diagnosis of Vulvovaginal Atrophy
The diagnosis of vulvovaginal atrophy is based on clinical assessment: anamnesis, evaluation of
the patient’s symptoms, and gynecological examinationwith the evaluation of clinical signs. In addition,
standardized scores and laboratory tests can be used such as the evaluation of vaginal pH and the
vaginal maturation index (VMI). The anamnesis should also include questions about sexual function,
the presence of decreased libido, and of dyspareunia. It is important to di↵erentiate superficial
dyspareunia, typical of vulvovaginal atrophy, from deep dyspareunia, typical of endometriosis.
Moreover, the sexual life of the couple should be investigated from the perspective of the new paradigm
of couplepause [24]. Avoiding sexual intercourse can exacerbate VVA as sexual activity can preserve
the vaginal epithelium by increasing blood flow and elasticity.
However, there is not always a correlation between clinical signs, laboratory data, and symptoms
and this represents an important limitation for diagnosis. Another issue is the subjectivity of the
diagnosis. One of the most commonly used scores is the vaginal health index (VHI) [25] for the
evaluation of vaginal elasticity, secretions, pH, the presence of petechiae on the epithelial mucosa, and
hydration. The score can vary between five and 25, with a cut-o↵ < 15 index of atrophic vagina. The
vulvar health index can be used to evaluate the vulva including vulvar inflammation, musculature
contraction, pain at speculum insertion, and epithelial integrity. The score can vary from zero to 24,
with a cut-o↵ > 8 index of atrophic vulva.
The VMI indicates the degree of tissue maturation, measuring the percentage of superficial,
intermediate, and parabasal cells. The maturation value (MV) is calculated with the following formula:
MV =% surface cells + (0.5 ⇥% intermediate cells) [26].
A pilot study proposed the use of trans-abdominal ultrasound to measure vaginal wall thickness
and total vaginal mucosal thickness at the bladder trigone [27]. Although the study is still preliminary,
this could represent a valuable tool for obtaining an objective evaluation of vaginal health and to
quantify the response to therapeutic interventions.
5. Treatment Options for Vulvovaginal Atrophy
5.1. Lubricants and Moisturizers
Various non-hormonal, non-prescription treatments exist for vaginal atrophy (VA), namely
increased coital activity, cessation of smoking, pelvic-floor physiotherapy (PT), and lubricants or
moisturizers [22]. Many women with VVA use over-the-counter (OTC) products such as vaginal
lubricants and moisturizers. International guidelines consider these to be the first line of therapy in
the treatment of VVA being free from significant contraindications and side e↵ects [28]. They can
be used alone or in combination with hormonal therapies as needed. This treatment option is also
recommended for women for whom the use of vaginal estrogen preparations is unacceptable. It is
important that osmolality, pH, and the composition of these products, either lubricants or moisturizers,
are similar to vaginal secretion [29].
The main di↵erence between vaginal lubricants and moisturizers is the timing of application.
Vaginal lubricants are particularly indicated for women whose main concern is vaginal dryness during
intercourse. Lubricants provide short-term relief from dryness and reduce dyspareunia. They can
be water-based, which are water-soluble and have a tendency to dry out; oil based, which are more
durable, but with a lower lubricating e↵ect; or silicone-based. Some lubricants contain glycerin,
propylene glycol, sweeteners and parabens, which may have an impact on the pH and osmolality of
water-based products [29].
Vaginal moisturizers are insoluble hydrophilic cross-linked polymers with a characteristic
bio-adhesiveness that is able to adhere to the epithelium of the vaginal wall by retaining water.
They can also contain a large amount of excipients that influence the pH and the osmolality of the
formulation. They can be used more regularly, rather than just in association with sexual activity, and
have a longer lasting e↵ect, improving the moisture of the vaginal mucosa and reducing the pH. The
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frequency of use is directly proportional to the severity of VVA [29]. The posology of the acute phase
consists in local applications in the evening, before going to bed, for seven to ten consecutive days,
so that they can act throughout the night, followed by two local applications per week to maintain
the beneficial e↵ects. The most commonly used moisturizers are based on hyaluronic acid (HA), a
glycosaminoglycan produced by fibroblasts, which is the main component of the extracellular matrix.
The possible action mechanism of hyaluronic acid is cell migration because it has a very high capacity
to bind water, which may facilitate cellular movement [30]. Thus, in the case of tissue damage, HA
may stimulate the migration and proliferation of fibroblasts and therefore the deposition of collagen
fibers, in addition to stimulating neo-angiogenesis and re-epithelialization. If used on a regular basis,
daily or every 2–3 days, HA based products improve symptoms of vaginal dryness, with an e↵ect
that has been compared with the e↵ect of topical estrogen therapy [31]. Some adverse e↵ects have
been reported with the use of HA [32], but most have occurred after injections. They include local
reactions namely bruising, erythema, swelling, and, rarely, more severe events such as tissue necrosis,
infection, or pulmonary complications. To the best of our knowledge, no severe adverse e↵ects have
been reported with the use of HA-based vaginal moisturizers.
Other possible components of vaginal moisturizers are ozonides, intermediate products of ozone,
which act as a biological reservoir preserving the therapeutic power of the molecule. In contact
with biological tissue, ozonides activate quickly, stimulating the local microcirculation to induce
neo-angiogenesis, promoting tissue repair, and inhibiting pro-inflammatory prostaglandins [33].
Oral vitamin D and vaginal vitamin E have been proposed for the treatment of VVA, but e cacy
data are limited and sometimes discordant. Vitamin D stimulates the proliferation of the vaginal
epithelium by activating the vitamin D receptor (VDR). Vaginal vitamin E is involved in the metabolism
of all cells and prevents tissue damage caused by oxidants. This facilitates blood circulation, which
consequently increases the metabolism of vaginal connective tissues and enhances the moisture and
flexibility of vaginal walls [34–36].
Oral and vaginal probiotics for improving vaginal microbiota may be beneficial for the treatment
of VVA symptoms, however, placebo-controlled trials that prove their e↵ectiveness are lacking [37].
Oral phytoestrogens are not e↵ective [38] while topical phytoestrogens seems to have a beneficial
e↵ect onVVA, improving genital symptoms,maturation index, vaginal pH,morphology, and expression
of estrogen receptors in the vaginal epithelium [39], however, these are preliminary investigations that
need to be verified in larger, prospective studies.
5.2. Hormonal Treatments
Hormone treatments of menopause (HTM), the association of estrogen-progestins, estrogen-
bazedoxifene, tibolone, or exclusively estrogens in hysterectomized women, have a beneficial effect
on many symptoms related to menopause including VVA. According to international guidelines, they are
not recommended in women who suffer only from vaginal and vulvar symptoms, however, when they are
used for primary indications, the evidence shows that HTM are able to restore the physiological vaginal pH,
the maturation index, and the thickness of the vaginal epithelium, its vascularization and lubrication [40].
Tibolone is converted into metabolites that have tissue-specific agonistic estrogenic (3-alpha
and 3-beta-hydroxytibolone) and progestogenic/androgenic (delta-4 tibolone) properties [41]. In
post-menopausal women, tibolone normalizes the maturation index, alleviates atrophic vaginitis
symptoms [42], and increases vaginal elasticity. Due to its androgenic activity, it has also been reported
to have positive e↵ects on sexual function [43].
The association of bazedoxifene with conjugated estrogens (BZA/CE), called tissue selective
estrogen complex (TSEC), has also been reported to be e↵ective in the treatment of moderate to severe
VVA and its symptoms. At week 12, the BZA/CE combination increased superficial cells, decreased
parabasal cells, decreased vaginal pH, and improved the most bothersome symptoms such as vaginal
dryness or dyspareunia [39].
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International guidelines recommend local hormonal therapy as a second step in the event of the
ine↵ectiveness of vaginal lubricants and moisturizers [40]. Options available include estradiol, estriol,
conjugated estrogens or promestriene gels, creams, ovules, tablets, or rings. These are specifically
indicated for the treatment of VVA including dyspareunia. All estrogen-based vaginal products are
more e↵ective than a placebo for VVA. Vaginal estrogens are superior to lubricants and moisturizers in
studies lasting at least six to twelve months [44,45].
The recommended dose is commonly a local daily application for two weeks as an attack therapy,
and then application twice a week as maintenance therapy [30].
Estrogen absorption is limited to low doses, but it is not eliminated, especially in the early phases
of treatment [45]. If the prescribed doses are taken, it is not necessary to associate a progestin for
endometrial protection. Clinical evidence from large observational studies such as the Women’s Health
Initiative Observational Study (WHI-OS) and the Nurse’s Health Study cohort did not find an increased
risk of endometrial cancer in women who used vaginal estrogens [46]. However, observational studies
have limitations and prospective, randomized controlled studies of long duration are lacking. The
placement site inside the vagina is important as this has been suggested to a↵ect the amount of estrogens
reaching the endometrium [47]. The risks of stroke, breast cancer, pulmonary embolism, and deep vein
thrombosis were not significantly di↵erent between vaginal estrogen users and non-users [46]. No
significant di↵erences in the safety profile of estradiol and estriol have been reported, while data on
promestriene are scarce [48].
5.3. Selective Estrogen Receptor Modulator (SERM): Ospemifene
Ospemifene is the only selective estrogen receptor modulator (SERM) to be indicated for the
treatment of VVA. It has been approved by the U.S. Food and Drug Administration (FDA) for the
treatment of moderate to severe dyspareunia and by the European Medical Agency (EMA) for the
treatment of moderate to severe VVA in women, with or without a uterus, who are not candidates for
local estrogen therapy [49]. It exerts a positive e↵ect on the vaginal epithelium while having, at the
same time, a neutral or minimal e↵ect on the other estrogen-dependent organs. In particular, it seems
to have a neutral e↵ect on the endometrium and the cardiovascular system, and an anti-estrogenic
e↵ect in pre-clinical studies on the breast. It is used at a dose of 60 mg daily.
The e↵ects on the signs of VVA are visible after four weeks of treatment such as the increase
of superficial cells, the reduction of basal cells, and the reduction of vaginal pH [50]. A significant
e↵ect on symptoms such as dryness and dyspareunia has been demonstrated to occur after 12 weeks
of treatment [51]. Recently, the e cacy of ospemifene at a histological level in both vaginal and
vulvar tissue has been demonstrated by observing increases in vaginal and vulvar epithelial thickness,
glycogen content, proliferation index, and an increase in vaginal estrogen receptor alfa (ER↵) [50,52].
Ospemifene has also been shown to improve atrophy of the vulvar vestibule and to normalize vestibular
sensitivity by increasing the perception threshold at a vulvar level [53]. In a short-term study, it has
also been shown to increase ratio type I and type III collagen at the vaginal level, suggesting possible
beneficial long-term e↵ects on vaginal connective tissue [52].
A current or previous thromboembolic event, vaginal bleeding of unknown origin, presence of
signs or symptoms of endometrial hyperplasia, malignant tumor dependent on sex hormones, and
ongoing breast carcinoma represent contra-indications. The EMA has also approved its administration
in women with a previous breast cancer after the completion of treatment including adjuvant therapy
and after performance of a control mammogram. The safety of this SERM on vaginal mucosa was
first demonstrated in phase II and III clinical studies and has now been on the market for six years in
the U.S. and for four years in some European countries including Italy. Ospemifene has an excellent
safety profile that has been demonstrated by both randomized, double-blind, multicenter phase II and
III placebo-controlled studies on a large number of patients, by the adverse event (AE) report and
by the Post-Authorization Safety Study (PASS). The thromboembolic risk appears to be lower than
with other SERMs. The incidence of cerebrovascular events was also lower in the cohort treated with
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ospemifene when compared to controls and in the cohort treated with other SERMs. Data on lipid and
coagulative profiles were just as good, therefore the cardiovascular risk seems to be limited. Observed
results regarding the risk of endometrial carcinoma meet the FDA criteria for endometrial safety. As
with other compounds in this class, ospemifene seems to be safe on the breast in in vitro studies, in
pre-clinical studies in animals, and in the surrogate parameters of breast safety [54–56].
5.4. Dehydroepiandrosterone (Prasterone)
Prasterone (dehydroepiandrosterone) has recently been introduced to the market for the treatment
of VVA. It acts as a precursor of intracellular sex steroid androgens and estrogens. Since the conversion
happens inside the cells, serum estradiol remains within the normal values for postmenopausal women,
thereby probably avoiding the risk of systemic e↵ects [57]. The e cacy of dehydroepiandrosterone
(DHEA) has been demonstrated in a prospective, randomized, double-blind, placebo-controlled phase
III clinical trial that examined the e↵ects of daily intravaginal prasterone (6.5 mg) on four co–primary
objectives, namely, the percentage of vaginal parabasal cells, percentage of vaginal superficial cells,
vaginal pH, and moderate to severe dyspareunia, identified by women as the most bothersome VVA
symptom. It may also be e↵ective on the reduction of libido with a possible action on nerve endings,
however, more scientific evidence is needed on this aspect [58].
Although data are limited to short-term studies on a relatively small number of patients, prasterone
seems to be very safe. The endometrium is not a↵ected by DHEA because the enzymes required to
transform DHEA into estrogens are absent in the endometrium. Although no systemic increase of
estrogen level has been reported, a history of breast cancer remains a contraindication.
5.5. Treatment Using Energy-Based Devices
5.5.1. Laser Therapy
A new trend gaining in popularity in the treatment of VVA is the advent of energy-based devices.
The most widely used are fractional microablative CO2 laser, non-ablative photothermal erbium:
yttrium aluminum garnet (YAG) laser, and radiofrequency (RF)-based energy devices.
Laser or RF waves act by heating the connective tissue of the vaginal wall to 40  C to 42  C. In this
way, they induce collagen contraction, neocollagenesis, vascularization, and growth factor infiltration
that ultimately revitalizes and restores the elasticity and moisture of the vaginal mucosa. The proposed
mechanism is the activation of heat shock proteins and tissue growth factors to stimulate new collagen
synthesis and epithelial remodeling [59].
Recent reviews have suggested some potential benefits with the use of this technology in treating
patients with VVA [60]. The e cacy of laser therapy in the treatment of VVA has been suggested by the
improvement of GSM symptoms, VHI scores, and female sexual function index (FSFI) in many studies
with its e↵ectiveness at least as good as that of local estrogen based treatments [61,62]. However, none
of these studies were sham or placebo controlled and the lack of su cient information, especially
concerning long-term safety, prompted the FDA in 2018 to warn against the indiscriminate marketing
of laser treatments [63].
Although authors generally suggest that the procedure is well tolerated, being rapid and painless,
increased vaginal pain, scarring, fibrosis, and vaginal wall lacerations have been reported [64].
The suggested treatment schedule involves three cycles at a distance of 30–40 days from each
other as an attack therapy, with one cycle per year as maintenance therapy. Studies do not show how
long the e↵ects persist if the treatment is stopped and how often the treatment can be repeated.
5.5.2. Radiofrequency Devices
Radiofrequency devices most commonly used by gynecologists are the transcutaneous
temperature-controlled radiofrequency (TTCRF), and more recently, the low-energy dynamic
quadripolar radiofrequency (DQRF). The mechanism of treatment is to trigger anatomical remodeling
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in the vaginal and vulvar tissues. There have been some small studies that prove its e↵ectiveness
on vaginal symptoms, sexual function as well as urinary symptoms, but again they have been small,
non-randomized studies [65–67].
5.5.3. Options for Treatment of Breast Cancer Survivors
In the case of women with previous or ongoing breast cancer, the options for treatment for
VVA are unfortunately limited. All hormone-based therapies are contraindicated including vaginal
isoflavone-based soy therapies, as there have been no studies on their safety in this cohort of
women. Non-hormonal approaches are the first-line choices during or after breast cancer [68].
The options therefore are to o↵er these women moisturizers and vaginal lubricants, laser or
radiofrequency treatments.
Another treatment that could be discussed with these women is ospemifene. Indeed, this SERM
has been approved by the FDA for its use in women with previous breast cancer who have completed
adjuvant therapy and have regular negative follow-ups. In cultured human breast tissue, ospemifene
has been shown to induce a downregulation of ER↵ expression and decrease the proliferation of the
cells, an e↵ect that is consistent with the proposed anti-estrogenic activity of this SERM at the breast
level [69]. In a recent small post-hoc analysis, a previous history of breast cancer did not appear to
a↵ect the e cacy or safety of ospemifene [54].
Finally, in this cohort of women, vaginal estrogen should be reserved for those patients who are
unresponsive to non-hormonal remedies. The decision to use vaginal estrogen should be made in
coordination with the woman’s oncologist. Importantly, an informed decision-making and consent
process in which the woman is provided with the information and resources to consider the benefits
and potential risks of vaginal estrogen administration should precede this decision [61]. Vaginally
administered estrogen can be absorbed in small amounts without raising blood levels, however, it may
potentially stimulate occult breast cancer and could interfere with tamoxifen or aromatase inhibitors
(AI) [70]. DHEA seems to be safe on breast tissue as it maintains serum estradiol within normal
post-menopausal values, thus avoiding the risk of systemic e↵ects. However, there have been no
studies in a cohort of breast cancer survivors.
6. Conclusions
VVA is still an under-addressed, under-diagnosed, and consequently under-treated condition. It
a↵ects the quality of life of millions of postmenopausal women. Although many treatment approaches
have been developed over the past decade, many still lack proper e cacy data and, more importantly,
safety data are still insu cient. More safety data are also needed for the treatment of this condition
in hormone-dependent breast cancer patients. Ospemifene, DHEA, and laser treatments seem
to be promising alternatives for patients who cannot use hormones; however, their safety needs
further research.
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Table A1. Prevalence of vulvovaginal atrophy according to the most recent surveys and studies.
Study Author Year Women’s AgeRange Method of Study Prevalence
“Women’s voices in the
menopause” survey Nappi et al. [7] 2010 55–65 years
Computer-assisted
web interviews 39%
VIVA survey Nappi et al. [8] 2012 55–65 years Online survey 45%
AGATA study Palma et al. [9] 2016 59 years(average)
Interview and
gynecological
examination
79%
The Women’s
EMPOWER Survey Kingsberg et al. [10] 2017 45–90 years Online survey 39–51%
EVES study Palacios et al. [5] 2018 45–75 years
Questionnaires and
gynecological
examination
90%
GENISSE study Moral et al. [12] 2018 30–75 years
Interview and
gynecological
examination
70%
ANGEL study Cagnacci et al. [13] 2019 40–55 years
Interview and
gynecological
examination
36.8%
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